Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
GlobeNewswire
CBX-250 is a first-in-class, potent, and specific T-cell engager for the treatment of myeloid leukemiaAbstract summarizing..